2018
DOI: 10.7727/wimj.2012.169
|View full text |Cite
|
Sign up to set email alerts
|

Salmonella enterica Arthritis in a Patient with Rheumatoid Arthritis Receiving Anti-tumour Necrosis Factor Therapy

Abstract: Anti-tumour necrosis factor (TNF) monoclonal antibodies have become an invaluable treatment against chronic inflammatory diseases such as rheumatoid arthritis (RA). However, due to increased risk of opportunistic infections, patients receiving anti-TNF therapy should be closely monitored for serious infections. Here, we describe a case of acute Salmonella enteritidis infection of a joint arthroplasty that previously was functioning well, in a patient receiving infliximab treatment for RA. After prolonged antim… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 4 publications
0
2
0
Order By: Relevance
“…Clinical drug development for rheumatologists has progressed slowly. RA patients are normally treated with disease-modifying anti-rheumatic drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs) [1,3], TNF inhibitors [4,5], IL-1 antagonists [6], and/or IL-6 receptor antibody [7,8]. Cumulatively, among the therapeutic approaches, none is curative for RA patients, leading investigators to search novel approaches for this common autoimmune disorder [9].…”
Section: Introductionmentioning
confidence: 99%
“…Clinical drug development for rheumatologists has progressed slowly. RA patients are normally treated with disease-modifying anti-rheumatic drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs) [1,3], TNF inhibitors [4,5], IL-1 antagonists [6], and/or IL-6 receptor antibody [7,8]. Cumulatively, among the therapeutic approaches, none is curative for RA patients, leading investigators to search novel approaches for this common autoimmune disorder [9].…”
Section: Introductionmentioning
confidence: 99%
“…Clinical drug development for the treatment of RA has progressed slowly. Usually, non‐steroidal anti‐inflammatory drugs (NSAIDs) 3,4 and other cytokine inhibitors such as TNF inhibitors, 5,6 IL‐1 antagonists 7 and IL‐6 receptor antibody 8,9 were used to treat RA. However, none are curative for RA.…”
Section: Introductionmentioning
confidence: 99%